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Introduction. Severe asthma occurs in 5 to 10% of asthmatic patients, with nasal polyposis as one 
of the most frequent comorbidity. Benralizumab was recently marketed, thus we could analyse its 
effects in real-life in severe asthma, and compare the effects of the drug in patients with and without 
polyposis. 
Methods. Patients with severe asthma, receiving Benralizumab were enrolled in Italian asthma 
centres. The efficacy criteria for asthma (exacerbation rate, oral corticosteroid intake, 
hospitalizations, pulmonary function, exhaled nitric oxide) were evaluated at baseline and after 24 
weeks of treatment. Patients were then sub-analysed according to the presence/absence of nasal 
polyposis.  
Results. Fifty-nine patients with severe uncontrolled asthma (21 males, age range 32-78) and 
treated with benralizumab for at least 24 weeks hasbeen evaluated, showing significant 
improvements in asthma-related outcomes, except for pulmonary function and exhaled nitric oxide. 
This included a reduction in the sino-nasal outcome-22 score versus baseline of 13.7 points 
(p=.0037) in the 34 patients with nasal polyposis. Anosmia disappeared in 31% patients (p=.0034). 
When comparing the groups with and without nasal polyposis, a similar reduction of exacerbations 
was seen, with a greater reduction of the steroid dependence in patients with polyposis (-72% vs -
53%; p<.0001), whereas lung function was significantly more improved (12% vs 34%, p=.0064) 
without polyposis patients. 
Conclusions. Benralizumab, after 6 months of treatment, confirmed its efficacy in severe asthma, 
and also in nasal polyposis, which is the most frequent comorbidity. The efficacy  of Benralizumab 
in reducing steroid dependence was even higher in pat ents with polyposis.  
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LIST OF ABBREVIATIONS 
OCS: Oral CorticosteroidS 
FEV1: Forced Expiratory Volume in 1 second 
FVC: Forced Vital Capacity 
FeNO: Fractional exhaled Nitric Oxide 
BEN: Benralizumab 
NP: Nasal Polyposis 
CRS: Chronic RhinoSinusitis 
SNOT-22: Sino Nasal Outcome Test 22 items  
INTRODUCTION 
Bronchial asthma is a chronic respiratory disease of increasing prevalence that affects an estimated 
300 million people worldwide [1] [2].  Among asthmatic patients 5 to 10% meet consensus criteria 
for severe asthma [3]; specifically they have poor control of symptoms despite a maximal inhaled 
therapy, frequent exacerbations, and/or the need for oral corticosteroid (OCS) (American Thoracic 
Society/European Respiratory Society (ATS/ERS) [4]. With the aim to reduce OCS intake, due to 
its well-known side effects (diabetes, cataract, oste porosis, hypertension, weight gain) [5,6], 
maintaining controlled asthma symptoms, to omalizumab [7,8] has been added mepolizumab, 
reslizumab, against interleukin (IL) 5 or its receptor alpha, in case of benralizumab [9][10,11]. The 
awareness that these molecules act on mechanisms of type-2 inflammation, common between 
asthma and several of its of comorbidities, including chronic rhinosinusitis with nasal polyps 
(CRSwNP, briefly NP) [12–16], prompt clinicians to observe the efficacy of monoclonal antibodies 
on both diseases [17]. The importance of NP in asthma ic patients stem from the fact that, it 
appeared to be one of the most frequent comorbidity bo h in clinical trials [14,18,19] and in the 
real-life setting [20]. Although not life-threatening, NP severely affects the quality of life of 
patients, contribute to the poor control of asthma, and is associated with a significant socio-
economic burden, due to repeated surgery and  use of OCS [21]. Particularly in severe asthmatic 
patients NP needs to be evaluated and an accurate follow-up program must be set, in the first 
instance with nasal fiberotic endoscopy eventually followed by CT scan [22][23]. 
The use of biological drugs in the treatment of sever  asthma has become a proven practice for 
some years now. Favourable effects in reducing exacerb tions, the use of OCS, in improving 
disease control in patients with severe asthma are well known. In recent years, research has been 
carried out with trials to evaluate the efficacy of biological drugs marketed for asthma on nasal 
polyposis [24]. Anti IL-5 drugs, both mepolizumab [25] and reslizumab [26], demonstrated a 
significant reduction of NP size after their administration. Also omalizumab (anti IgE), demonstrate 
its efficacy in reduction of NP size after administration [27]. Finally dupilumab (anti IL-4r) has 
proved its effectiveness in NP size reduction and impact of the disease in affected patients [28]. 
There are much less data about Benralizumab (BEN), an antagonist of the IL-5 receptor. It inhibits 
the maturation, activation and survival of eosinophils and, via a cell-mediated cytotoxicity 
mechanism, also provoke apoptosis and induce eosinophil depletion (ADCC). BEN was recently 
commercialized in Italy for severe asthma.  
Given the increasingly central role of real life studies, following the suggestions of Thorpe et al, and
their PRECIS tool [29],  in the present study we describe the effects of BEN, given for at least 6 
months in asthma and compare the effect of the treatment in subjects with or without NP.  
METHODS 
Study design is an observational retrospective multicen re study. Source of population are 
database about multiple Italian Centres (Genoa, Arenzano, Turin, Verona, Brescia, Sestri Levante, 
Naples, Rome, Cuneo, Pietra Ligure, Bergamo, Milan and Bari). 
Inclusion criteria. Patients aged ≥ 18 year old, with diagnosis of severe asthma, according to 
ATS/ERS definition, eligible to BEN treatment according to GINA guidelines and to the Italian 
prescription rules (blood eosinophils ≥300 cell/mcl, ≥ 2 exacerbations requiring systemic steroids in 
the previous 12 months or steroid dependence for at least 6 months). All patients were fully 
adherent to the prescribed maximal inhaled therapy (GINA step 5) and underwent a detailed 
diagnostic work-up before receiving the diagnosis of severe asthma, and BEN prescription, 
including thoracic CT-scan, allergy testing and plethysmography. When needed, in the clinical 
suspect of NP, maxillary CT-scan and/or fiberoptic rhinoscopy were performed. The first 
consecutive patients, who were treated with BEN in the various clinics involved in the study, were 
considered. Patients needed to be treated for 6 months, with BEN, in the period from 1st December 
2018 to 31st August 2019.  
No exclusion criteria were envisaged for this study.  
The evaluated parameters were: exacerbation rate and hospitalizations (compared to the 
previous 12 months), asthma control test (ACT) score, Forced  Expiratory Volume 1 second 
(FEV1), Forced Vital Capacity (FVC), fractional exhaled nitric oxide (FeNO), eosinohil blood 
count. All the parameters were recorded at baseline (before treatment) and at 24 weeks. Also, the 
OCS intake, and the chronic need for OCS were carefully assessed at the same time points. NP was 
evaluated, in addition to the instrumental diagnosis, by the sino-nasal outcome test with 22 items 
(SNOT-22) and by the subjective patient’s perception of anosmia (yes/no).  
Main study endpoints was to observe the efficacy of BEN in the whole population, about the 
variation of exacerbations, OCS dependence and dosage, lung function tests and asthma control 
(measured with ACT).  Further endpoint was to observe the effect of BEN in two distinct 
population, patients with or without NP, also evaluating the efficacy on nasal symptoms (measured 
with SNOT-22 test). 
Data were analysed by descriptive statistics. Comparisons between groups were made by t-
test, chi-square test, Fisher’s exact test where necessary. A p value of ≤0.05 was considered 
significant. 
RESULTS 
Fifty-nine patients (64% female, age range 32-78), referred to 12 severe asthma clinics in 
Italy starting from December 1st  2018 received BEN and could be evaluated for at le st 24 weeks. 
The clinical and demographic data of the population are summarized in TABLE 1 . After 24 weeks 
of treatment, there was a significant improvement in almost all of the considered asthma-related 
parameters, as shown in TABLE 2 . The control of the disease, measured with ACT score, showed 
an overall improvement of 47 % (p<.0001 versus baseline). The results are detailed in TABLE 2 
and FIGURE 1. After 24 weeks of therapy 48 (81%) patients  have reached the minimal clinical 
important difference (MCID) for ACT, fixed at 3 points [30]. No further observations about MCID 
could be done due to the unviability of similar parameters in other evaluated outcomes [31]. 
 
The mean number of  asthma exacerbations decreased from 4.44 to 0.39 (-91%; p<.0001) 
and hospitalizations decreased from 0.31 to 0.03 (-89%; p<.0001). The number of patients 
chronically receiving OCS went down from 41/59 to 15/59 and the mean OCS daily dose decreased 
by 54% (12.0 to 5.6 mg, p<.0001). There was also an increase in the absolute values of FEV1 and 
FVC, 17% and 11%, respectively, but without a statiically significant difference.  
Thirty-four (58%) out of 59 patients (19 female, mean age 56 ± 11 years, age range 32-78 
years) had an ascertained concomitant NP, confirmed by TC scan and/or fiber-optic rhinoscopy. In 
those patients the mean number of previous surgical interventions (ranged between 1 and 8) was 
2.8±2.0, the SNOT-22 score was 58 ± 18, and 76% of them reported a concomitant anosmia. After 
24 weeks of treatment 20 (54%) patients reduced their SNOT-22 score more than 8.9, fixed value 
for MCID of the test [32]. The details of patients with and without NP are summarized in TABLE 
3. When comparing the two subpopulations (with and without NP), some differences could be seen. 
The pulmonary function (FEV1 in absolute value and % predicted) improved significantly versus 
baseline only in patients without NP, and the same happened for FeNO. On the contrary, the 
percentage of subjects who were on chronic OCS treatment decreased significantly only in patients 
with NP (TABLE 4, FIGURE 2 ).    
Concerning the safety, no patient had to discontinue the treatment due to adverse events. 
Adverse events occurs in 9 (15%) patients, with fever on the day of first administration as the most 
common one (4 patients; 6.8%) and 2 (3.4%) patients with Herpes Zoster Virus infection. Other 
adverse events individually reported were headache, back pain and urticarial. 
 
DISCUSSION 
In the last two decades, biological treatments were commercialized for severe asthma, and 
the results obtained firstly with anti-IgE (Omalizumab) and subsequently with IL-5 antagonists 
(Mepolizumab, Benralizumab) lead to relevant advances in the management of the disease. These 
include the direct clinical aspect (asthma control, pulmonary function, exacerbation rate, 
hospitalizations) and the sparing effect on OCS use, with its long-term implications. It was 
observed that real-life data and patients’ characteistics  [18, 21] partly diverge from the results of 
regulatory trials, therefore real-life data improved our knowledge on the clinical effects, safety and
indications of the new drugs [34]. BEN was licensed in many Countries for the treatment of severe 
asthma, and in Italy less than one year ago. We can provide nowadays the efficacy data of this 
recently marketed  drug, over a period of at least 6 months in real life.  
Comparing several aspects of RCTs and RL studies, particularly about our patients and the 
one randomized in main BEN studies, was possible to observe several differences. One of the first 
observation is regard baseline eosinophils count, resulted highest in our patients if compared with 
the one of CALIMA [35] and SIROCCO [36]. A second interesting difference regards the 
prevalence of nasal polyps in the two different population. As already observed in mepolizumab 
trials [20], if compared with RCTs, NP prevalence is considerably higher in RL also in this trial 
with BEN. A reason of these variance could be find in the different inclusion and exclusion criteria 
about RL and RCTs studies, where the real patients have less restrictions to be enrolled in a study. 
In our trial, in fact, inclusion and exclusion crite ia, above described, are less strict, requiring almost 
only the diagnosis of asthma and the prescription criteria for BEN.  
The herein reported results confirm the clinical efficacy and the biological effects of BEN in 
real life and its safety. In particular, there was an apparent improvement in asthma control, in the 
exacerbation rate, in OCS intake and biological markers (FeNO, blood eosinophils). It is true that 
the efficacy results in this real-life population, still not allow to identify the right patient for the 
right prescription. Another limitation of our study is that we could assess the data of exacerbations 
and OCS intake over a 6-month period, and those data are  compared to the historical over 1 year. 
Nonetheless, the difference between baseline and 6 months were apparent.  
There is another aspect of clinical relevance: in severe eosinophilic asthma, NP represents a 
frequent comorbidity, with a well-recognized impact on the quality of life, on the costs and on the 
control of asthma itself. In the herein observed population, an ascertained NP was present in 58% of 
patients, thus we could evaluate both the effects of the drug, and to dissect those effects between 
patients with or without NP.  
After 24 weeks of therapy, the cohort of patients with NP had a significant improvement in 
SNOT-22, by 23.8% compared with the baseline value. Actually, the literature on the possible 
effects of BEN in NP associated to severe asthma is, so far, scarce [37] [36,38]. One of the worst 
symptom associated with NP is anosmia. Patients with th s symptom are more commonly anxious 
and depressed than patients without anosmia [39]. We could evidence the improvement of the 
symptom in 31% of patients affected by anosmia at baseline (p=.0034), as previously reported as 
case description. [40]. 
 Overall, after 24 weeks, BEN treatment in real life was confirmed and the efficacy was also 
apparent on the concomitant NP, when present. In the subset of patients with NP the reduction of 
OCS dependence was greater than in patients without NP, while the opposite was seen for the 
respiratory function.  
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Table 1. Descriptive statistics of the population at baseline 
Baseline (n=59) Total population (n=59) NP (n=34) No NP (n=25) 
Male/Female  21/38 19/15 19/6 
Age range 32-78 32-78 47-78 








Exacerbations per year, 
mean ± SD 
(range) 









Hospitalizations per year,  
mean ± SD 






OCS-dependent, n (%) 41 (69) 25 (73) 19 (76) 
OCS intake mg/day, mean 
± SD  
12.0 ± 8.1 
(2.5 – 25) 
9.04±8.01 
(2.5 – 25) 
14.4±9.4 
(5 – 25) 
FEV1 L, mean ± SD  1.92 ± 0.76 
(0.61 – 4.43) 
2.16±0.73 
(0.66 – 4.43) 
1.47±0.63 
(0.61 – 2.79) 
FeNO ppb, mean ± SD 70 ± 58 59±31 82±79 
  (5 – 406) (17-156) (5-406) 
 Eosinophils cells/μl, mean 
± SD  
581 ±556 
(70 – 3350) 
632±397 
(70 – 1600)  
567±733 
(100 – 3350) 
Perceived anosmia (%) 26 (44) 26 (76) - 
 
Table 2. Changes in the severe asthma-related outcomes (whole population N= 59) 
All data are expressed in mean ± standard deviation. * previous 12 months before treatment; 
**geometric mean;  n.s. = not significant. 
  
 Baseline 24 weeks p-value 
ACT 15 ± 4 21 ± 4 <.0001 
Exacerbation rate* 4.44 ± 3.52 0.39 ± 1.12 <.0001 
Hospitalizations * 0.31 ± 0.56 0.03 ± 0.18 0.0006 
OCS dependent n (%) 41 (69) 15 (25) <.0001 
OCS dose (mg prednisone) 12.0 ± 8.1 5.6 ± 3.58 <.0001 
FEV1 (L) 1.92 ± 0.76 2.25 ± 0.82 n.s. 
FEV1 (%) 72 ± 20 86 ± 18 n.s. 
FeNO ppb  70 ± 58 42 ± 42 n.s. 
Eosinophils (cell/mcl) ** 581 ± 556 24 ± 48 <.0001 
 
Table 3. Difference of outcomes, after 6 months of therapy, in population with and without NP 
All data are expressed as mean and standard deviation (SD) or value and percentage (%) where not differently specified. ¥ 12 months at baseline 
and in the period of treatment after 6 months, *value expressed in geometric mean. # expressed in predisone equivalent. n.s. = statistically not 
significant. 








No NP (n=25) 
Baseline 







ACT 15 (4) 21 (4) 6 (39%) <.0001 13 (3) 21 (4) 8 (62%) <.0001 
Exacerbations¥ 4.7 (3.8) 0.35 (1.37) - 4.36 (- 93%) <.0001 4.1 (3.5) 0.44 (0.71) -3.64 (- 
89%) 
<.0001 
Hospitalizations 0.18 (0.39) 0.06 (0.24) - 0.12 (- 67%) n.s. 0.48 (0.71) 0.0 (0.0) - 0.48 
(100%) 
.0015 
OCS dependent 25 (73%) 7 (21%) - 18 (- 72%) <.0001 19 (76%) 9 (36%) -10 (- 53%) .0096 
OCS dose#  9.04 (8.1) 3.5 (1.7) - 5.54 (- 61%) <.0001 14.1 (9.4) 6.25 (4.2) - 7.85 (- 
56%) 
.0002 
FEV1 (L) 2.16 (0.73) 2.34 (0.79) 0.18 (8.3%) n.s. 1.47 (0.63) 2.09 (0.90) 0.62 (42%) .0318 
FEV1 (%) 76 (18) 85 (18) 9 (12%) n.s. 66 (22) 88 (18) 22 (34%) .0005 
FVC (L) 3.27 (1.07) 3.43 (1.05) 0.16 (4.9%) n.s. 2.31 (0.77) 3.00 (1.20) 0.68 (30%) n.s. 
FVC (%) 94 (18) 101 (21) 7 (5%) n.s. 80 (26) 98 (24) 18 (22%) n.s. 
FeNO 59 (31) 49 (44) -10 (- 18%) n.s. 82 (79) 36 (41) - 45 (55) .0280 
Blood eosinophils* 632 (397) 14 (47) - 618 (- 98%) <.0001 567 36 (49) 531 (94%) <.0001 
SNOT-22 57.6 (18) 44.0 (19.8) - 13.7 (- 
23.8%) 
.0037 n.a. n.a. n.a. n.a. 




Table 4. Comparison of the change in the evaluated parameters between patients with and 
without NP  
 NP  
(Δ 24 week – 
baseline) 
No NP  
(Δ 24 week – 
baseline) 
p-value 
ACT 6 (39%) 8 (62%) n.s. 
Exacerbations¥ - 4.36 (- 93%) -3.64 (- 89%) n.s. 
Hospitalizations - 0.12 (- 67%) - 0.48 (100%) .0168 
OCS dependent - 18 (- 72%) -10 (- 53%) <.0001 
OCS dose#  - 5.54 (- 61%) - 7.85 (- 56%) n.s. 
FEV1 (L) 0.18 (8.3%) 0.62 (42%) .0414 
FEV1 (%) 9 (12%) 22 (34%) .0064 
FeNO -10 (- 18%) - 45 (- 55%) .0358 
Blood eosinophils* - 618 (- 98%) - 531 (- 94%) n.s. 
 
¥ 12 months at baseline and in the period of treatmn  after 24 weeks, *value expressed in 
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Figure 1: Changes in the main asthma evaluation parameters between baseline and 6 months. 
Figure 2. A) Exacerbations mean change, B) steroid dependent patients percentage reduction, C) 
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• Treatment of severe asthma is deeply changed with the development of biologicals 
• Benralizumab is effective both in RCTs and in Real-life setting 
• CRSwNP is a common comorbidity in severe asthmatic people 
• Benralizumab proved to be effective both in patients with or without CRSwNP 
• Benralizumab proved to be effective in reducing nasal symptoms in CRSwNP patients 
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